Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple … – Odessa American
|
Legend Announces FDA clearance of IND application on CAR–T immuno-cell therapy for the Treatment of Multiple …
Odessa American of LCAR-B38M (JNJ-68284528), a Chimeric Antigen Receptor T cell. (CAR-T) therapy. Scheduled to begin enrollment in the second half of. 2018, the Phase 1b/2 study (68284528MMY2001) is part of a. collaboration between Legend Biotech and Janssen … Janssen (JNJ) Announces Initiation of Phase 1b/2 Clinical … |
